KBC Securities - Amoeba SA (AMEBA) Amoéba Presenting the 2025 results of its vineyard trial campaign

Report

KBC Securities

Guy Sips

Amoéba Presenting the 2025 results of its vineyard trial campaign

We welcome AXPERA confirms its effectiveness against downy mildew and its strong potential to significantly reduce copper use. These field trials were confirming AXPERA's strong performance in real conditions.
Amoéba presented nice results of its 2025 vineyard trial campaign confirming AXPERA's effectiveness against downy mildew, as observed in previous years — and particularly in 2024, a season during which the disease proved especially virulent.
The results obtained in 2025 confirm that the integration of AXPERA —1 to 4 applications, alone or in combination with a reduced dose of copper (1 to 2kg/ha/year)—offers performance equivalent to that of a conventional program or a standard copper program of 3kg/ha/year, i.e. 70 to 80% effectiveness on bunches, thus enabling a reduction in copper use of up to 66%. These findings confirm the robustness and consistency of AXPERA, already observed in 2024, a year marked by an exceptionally high downy mildew pressure.
Our Buy rating and €1.5 TP are based on the expectation of a commercial launch in 2026.

29/10/2025 1 EN

Underlying

Amoeba SA

Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.

See profile

FR0011051598 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Other Reports on these Companies

KBC Securities

Amoéba Obtaining market authorisation in US for its AXPERA biocontrol solution

We welcome Amoéba's first two biocontrol fungicides, AXPERA NOA and AXPERA GREEN, received approval from the US Environmental Protection Agency (US EPA) for the first crops targeted by Amoéba. Amoéba also indicated it is progressing in line with its strategic plan to begin marketing its biocontrol solution in Europe and the US in 2026. Amoéba announced that it has received regulatory approval from the US Environmental Protection Agency (EPA) to market in the US its biocontrol products AXPERA NOA and AXPERA GREEN, based on the lysate of Willaertia magna C2c Maky. We look forward to the com...

October 17, 2025 October 17, 2025 1 EN

KBC Securities

Amoéba Setting up Green 4 Agro, structuring its activities in biocontrol

Amoéba takes a further step in the structuring of its activities in the area of biocontrol, confirming its ambition to become a key player in the agroecological transition by setting up Green 4 Agro, its subsidiary dedicated to the commercialisation and development of its biocontrol and biostimulant solutions. As a reminder, commercial operations will begin in 2026 with the distribution of its AXPERA biocontrol solution for vineyards and vegetable crops, through its first partner, Koppert. Green 4 Agro is wholly owned by Amoéba. This development will enable them to set up a specific organisat...

October 16, 2025 October 16, 2025 1 EN

Biotalys EPA issues proposed registration decision for Evoca

We increased our Target Price for Biotalys to € 7.5 (was €6.1) while maintaining our Buy rating after Biotalys announced that the US EPA (Environmental Protection Agency) has issued its proposed registration decision to approve its first biofungicide, Evoca. The EPA will now initiate the final phase in its regulatory review, allowing stakeholders such as growers and industry associations 15 days to provide feedback before finalizing its regulatory decision. The EPA has also posted a final rule exempting Evoca's active ingredient residues on treated crops from tolerance requirements, indicating...

14h / 22m 14h / 22m 1 EN

Lynn Hautekeete

Lynn Hautekeete

Eurocommercial Properties 3Q25 results: Italy continues to outperform

Eurocommercial reports results in line with our expectations at EUR 1.85 direct investment result per share vs. 1.83 KBCSe (+1.1% YoY). The rental income growth accelerated at 3.6% like-for-like (1.7% above inflation) driven by rent reversion, stable (+10bps) vacancy and higher retail sales (+4.1% vs 2.6% in 1H25). The like-for-like growth is mainly driven by the Italian portfolio at +5.1%. The average rent collection dropped from 99.0% to 98.0% coming from the French portfolio (92% in 3Q25). The average debt maturity decreased to 3.3y from 3.6y in 1H25. In the short run, Eurocommercial has t...

14h / 44m 14h / 44m 1 EN

Guy Sips ... (+8)

Guy Sips
Hilde Van Boxstael
Jacob Mekhael
Kristof Samoy
Livio Luyten
Lynn Hautekeete
Thomas Couvreur
Wim Hoste

Morning Notes : FUR NA, GLPG NA, MTLS US, QFG BB, XFAB FP, BTLS BB, SYENS BB, ECMPA NA

: FUR NA, GLPG NA, MTLS US, QFG BB, XFAB FP, BTLS BB, SYENS BB, ECMPA NA

14h / 51m 14h / 51m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Amoéba Presenting the 2025 results of its vineyard trial campaign

We are a financial services provider for several types of professional clients, each with distinct needs.

Amoéba Obtaining market authorisation in US for its AXPERA biocontrol solution

Amoéba Setting up Green 4 Agro, structuring its activities in biocontrol

Biotalys EPA issues proposed registration decision for Evoca

Eurocommercial Properties 3Q25 results: Italy continues to outperform

Morning Notes : FUR NA, GLPG NA, MTLS US, QFG BB, XFAB FP, BTLS BB, SYENS BB, ECMPA NA

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe